0.04Open0.04Pre Close0 Volume56 Open Interest3.00Strike Price0.00Turnover3224.91%IV50.50%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1395Delta0.3451Gamma50.50Leverage Ratio-1.9769Theta0.0000Rho7.05Eff Leverage0.0000Vega
Amylyx Pharmaceuticals Stock Discussion
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has recently announced the acquisition of avexitide from Eiger BioPharmaceuticals, Inc. Avexitide has already garnered considerable attention for its potential therapeutic benefits and has received designations from the U.S. Food and Drug Administration (FDA). This article delve...
Dow Jones· 11 mins ago! Is to enter Phase 3 Trial in Q1 2025!
No comment yet